Drug Profile
Insulin glargine biosimilar - GEROPHARM
Alternative Names: Insulin RinGlarLatest Information Update: 21 Apr 2022
Price :
$50
*
At a glance
- Originator GEROPHARM
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 21 Apr 2022 No development reported - Phase-III for Type 1 diabetes mellitus in Russia (SC) (Geropharm pipeline, April 2022)
- 15 May 2019 Geropharm completes a phase III trial in Type 1 diabetes mellitus in Russia (NCT04022993)
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus in Russia (SC)